A Cell paper by Montel-Hagen et al. (2008) published last year addresses the comparative physiology of ascorbate recycling in erythrocytes (Montel-Hagen et al., 2008) . The authors claim in this paper that GLUT1-mediated glucose transport decreases whereas GLUT1-mediated dehydroascorbate (DHA) transport increases during erythropoiesis despite markedly enhanced GLUT1 expression.
To support these claims, the authors measured the uptake of the phosphorylatable analog of glucose, 2-deoxy-D-glucose (2DG), at different stages of erythropoiesis in CD34 + human hematopoietic progenitor cells stimulated to differentiate by erythropoietin. They observed that the ratio of GLUT1 mRNA to GAPDH mRNA increased over 12 days of differentiation by 1000-fold; large increases in GLUT1 expression were also observed by immunoblot analysis. A 4-fold decrease in the rate of labeled 2DG accumulation was observed between day 0 and day 8, whereas with DHA uptake (also transported via GLUT1), there is approximately a 3-fold increase in uptake between day 0 and day 8. These apparent differences are ascribed to a large increase in stomatin expression during the red blood cell maturation process, which could lead to sequestration of GLUT1 within lipid rafts causing inhibition of glucose transport. In support of this hypothesis, the authors showed that 2DG uptake in erythrocytes from two patients with stomatin deficiency was increased by 50%, whereas DHA uptake was decreased by 40%.
Unfortunately, interpretation of these data may be obscured by the method used to monitor 2DG uptake. The authors monitored 2DG uptake in CD34 + cells at room temperature for 30 s at a concentration of 0.5 µM. Uptake of 2DG and DHA in control erythrocytes and in erythrocytes from patients was measured over incubation times of 10 min ( Figure 5C in the Cell paper). At these concentrations and temperatures, sugar equilibration in human erythrocytes occurs within 1-2 s (Carruthers, 1990; Lowe and Walmsley, 1986) . It is therefore difficult to see how a difference in transport in human erythrocytes can be ascertained by this methodology. Rather, these measurements report the cellular 2DG space, which comprises cell water (equilibrated in 1-2 s) and a metabolic sink (ongoing over 10 min).
The authors indicated that they observed competitive inhibition of 2DG uptake with 5 mM glucose. This will indeed reduce uptake of label via the GLUT1 glucose transporter but also will reduce uptake of label into the hexose phosphate pool. They also state that uptake of the nonmetabolizable sugar 3-O methylglucose is inhibited by 5 mM glucose over a 60 s time period. However, this information is not germane to the comparative data regarding 2DG uptake. We think that all of the differences in radiolabeled 2DG uptake must be due to incorporation of the sugar into the hexose phosphate pool. To the extent that there are differences, these can only reflect changes in the activities of the glycolytic enzymes, hexokinase, and perhaps also glucose-6-phosphate dehydrogenase, rather than GLUT1 activity. Consistent with this notion is the 90-to 150-fold downregulation of hexokinase that occurs during erythroblast maturation in humans (Shinohara et al., 1985) and rabbits (Magnani et al., 1984) , which may result from ATPand ubiquitin-dependent proteolysis of hexokinase (Magnani et al., 1986) .
It is also probable that the rate of DHA transport is underestimated. The reported lack of inhibition of DHA uptake by glucose in red blood cells is inconsistent with previous findings in human erythrocytes (Mann and Newton, 1975) , oocytes heterologously expressing GLUT1, GLUT3, or GLUT4 (Rumsey et al., 1997 (Rumsey et al., , 2000 , and rat adipocytes expressing GLUT1 and GLUT4 (Rumsey et al., 2000) . This suggests that DHA uptake was measured at time points where intracellular recycling to ascorbate, rather than partially inhibited DHA transport, is rate limiting for intracellular accumulation of radiolabel.
We do not question the reproducibility of Montel-Hagen's data, only the interpretation. Although the capacity for and rate of sugar transport in human erythrocytes is large, the use of tracer concentrations of 2DG means that 2DG phosphorylation by intracellular hexokinase will constitute a large component of net radiolabel uptake even at the earliest time points recorded at low temperatures. Thus, linearity of 0.5 µM 2DG uptake by human red blood cells at early time points cannot be ascribed solely to transport. Rather, it is ambiguously affected by intracellular metabolism. At later time points (>5-10 s), even at or above 4°C, when cytosolic free sugar has fully equilibrated with the extracellular sugar pool, net uptake is solely dependent on the rate of 2DG metabolism. The only way to unambiguously define a deficit in glucose transport under the conditions used by MontelHagen et al. is to measure glucose flux with a nonmetabolizable analog, such as 3-O-methyl-D-glucose. This has not been done and thus at present there is no good evidence supporting the contention of differential GLUT1 transport function during erythropoiesis.
Of all cells in the human body, erythrocytes express the highest level of the GLUT1 glucose transporter, with more than 200,000 molecules per cell (Mueckler et al., 1985) . We found that GLUT1 expression is significantly upregulated in late-stage erythroblasts, whereas glucose transport is decreased (Montel-Hagen et al., 2008a) . This increase in GLUT1 expression was associated with enhanced transport of L-dehydroascorbic acid (DHA), an oxidized intermediate of ascorbic acid (AA). Moreover, the efficient capture of DHA by erythrocyte GLUT1 and its immediate reduction to AA constitutes a recycling system that has evolved in those mammals incapable of synthesizing vitamin C. This system differs markedly from that observed in the adult erythrocytes of other species, which do not express GLUT1 and do not transport DHA. Thus, GLUT1 expression by erythrocytes is specifically associated with increased DHA transport, whereas erythrocyte glucose uptake can be achieved using other GLUT transporters.
Glucose Transport in Human Blood Cell Progenitors
Carruthers and Naftalin question whether our measurements of glucose uptake (2-deoxyglucose, 2DG) in human erythroid progenitors reflected decreased hexokinase activity rather than changes in actual transport. They base their argument on reference publications stating that hexokinase activity is high in erythroblasts and is downregulated during erythroid differentiation (Magnani et al., 1984; Shinohara et al., 1985) . However, this argument is spurious as we demonstrated that glucose transport is already decreased in human immature erythroblasts (Montel-Hagen et al., 2008a) , where the hexokinase activity is very high (Magnani et al., 1984) .
To further corroborate these data, we performed glucose uptake studies at early time points during erythroid differentiation induced by recombinant erythropoietin (rEPO), when most cells are proerythroblasts or basophilic erythroblasts (for example, see Giarratana et al., 2005; Figure 1A in Montel-Hagen et al., 2008a) . These immature erythroblasts have high hexokinase activity (Magnani et al., 1984; Shinohara et al., 1985) , but we still performed transport assays on ice in order to minimize variations in enzymatic activity. As demonstrated in kinetic analyses, glucose transport in early erythroblasts (day 3 of differentiation) was significantly decreased compared to that in CD34 + hematopoietic progenitor cells, at time points as early as 1 s (see day 0 versus day 3 in Figure  S1A of this Response, available online). We also addressed the relative contributions of glucose transport and hexokinase activity by assessing the uptake of 3-O-methylglucose (3-OMG) at an early time point of erythropoiesis (day 2 of differentiation). These uptake data (see Figure S1B here), using a nonmetabolizable sugar analog, remain concordant with our previous experiments, thereby addressing the concern raised by Carruthers and Naftalin. We can indeed assert that diminished glucose uptake during erythroid differentiation of CD34 + progenitor cells results from decreased glucose transport.
GLUT1-Mediated DHA Transport
We also demonstrated that GLUT1-mediated DHA uptake in human red blood cells is not inhibited by glucose. Carruthers and Naftalin state that these results are inconsistent with previous findings, but they miss the key point that erythrocytes differ from other cell types. In nonerythroid cells, glucose indeed inhibits GLUT1-mediated DHA uptake, as shown by several groups (for example, see Rumsey et al., 1997; Montel-Hagen et al., 2008a) . The sole publication that Carruthers and Naftalin cite to support their claim that glucose competitively inhibits DHA uptake in erythroid cells dates from 1975 and is quoted out of context. This elegant study, performed years before GLUT1 was identified, used supraphysiological glucose concentrations to compete away DHA (Mann and Newton, 1975) . This study has since been refuted by key publications demonstrating efficient and rapid DHA uptake by erythrocytes, even in the presence of a 50-fold molar excess of glucose (for example see Mendiratta et al., 1998) . Our results (Montel-Hagen et al., 2008a and Figure S2 here) are in complete agreement with these latter studies. Thus, Carruthers and Naftalin seem to have overlooked published literature documenting differences between erythrocytes and nucleated cells. Moreover, a recent publication has shown that glucose does not affect DHA uptake in infant dog erythrocytes expressing high levels of GLUT1 (Ogawa, 2009) . Thus, in erythrocytes, physiological glucose concentrations do not competitively inhibit GLUT1-mediated transport of DHA.
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